(Q37301964)

19 August 2017

1 reference

title

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa (English)

1 reference

19 August 2017

Stefan Schulte

1

1 reference

19 August 2017

language of work or name

1 reference

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

122 Suppl 4

1 reference

19 August 2017

page(s)

S14-9

1 reference

Mechanism of action of recombinant activated factor VII: an update

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

Pharmaceutical strategies utilizing recombinant human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

Development of a long-acting insulin analog using albumin fusion technology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

Prolonged in-vivo half-life of factor VIIa by fusion to albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970029-X

7 January 2021

10.1016/S0049-3848(08)70029-X

Identifiers

DOI

1 reference

19 August 2017

1 reference